Understanding Myeloid Cancers and the Role of RNA

Myeloid cancers, including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS), often arise due to complex genetic alterations, particularly gene fusions and translocations. RNA sequencing plays a crucial role in detecting these changes, providing a deeper understanding of disease mechanisms and aiding in targeted therapeutic decisions.

Addressing Challenges with the Uncoded Myeloid Profiler RNA Panel

Identifying gene fusions in myeloid cancers can be challenging due to their diversity and low abundance in samples. The Uncoded Myeloid Profiler RNA Panel overcomes these obstacles by offering a highly sensitive and specific solution designed to detect over 52 fusion genes and more than 600 fusion variants. With its robust target enrichment and streamlined workflow, this panel enhances diagnostic accuracy, facilitates research, and supports precision oncology approaches.

Product Overview

The Uncoded Myeloid Profiler RNA Panel is a next-generation sequencing (NGS)-based assay designed for comprehensive fusion gene detection in myeloid malignancies. Using efficient RNA capture technology, it enables the identification of known and novel fusions, making it a powerful tool for translational research and clinical applications.